To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.
Histologically diagnosed marginal zone lymphoma (any subtypes)
Have received at least 1 prior treatment including CD20 monoclonal antibody
Patients have relapsed or refractory disease to their most recent regimen
Stage II, III or IV disease
Known active central nervous system lymphoma or leptomeningeal disease.
Treatment with any chemotherapeutic agent, or treatment with any other anti-lymphoma agent (investigational or otherwise) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to first investigational agent administration.
Adequately treated localized skin cancer without evidence of disease.
Adequately treated or monitored low risk localized prostate cancer.
Single group
Mosunetuzumab
DrugGiven by IV
Zanubrutinib
DrugGiven by IV
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Click on the lead sponsor to view all of their trials.
